This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
This is a phase 2b, randomized, double-blind, placebo-controlled study designed to assess the dose-dependent effects of 3 doses of the corticotropin-releasing factor type 2 (CRF2) peptide agonist, COR-1167, in subjects with WHF, defined as subjects requiring urgent administration of intravenous (i.v.) diuretics due to worsening of signs and symptoms of heart failure (HF) associated with volume overload
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
300
Natriuresis
Urinary sodium excretion
Time frame: 24 hours
Body weight
Changes in body weight
Time frame: 7 days
NT-proBNP
Changes in NT-proBNP
Time frame: 7 days
Kansas City Cardiomyopathy Questionnaire (KCCQ)-Total Symptom Score (TSS)
Changes in KCCQ-TSS - The score ranges from 0 to 100 with higher score indicating a better health status
Time frame: 28 days
Left Atrial Volume index (LAVi)
Changes in LAVi - LAV-i is an index of cardiac function measured by echocardiogram
Time frame: 2 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Indiana University Health Methodist Hospital
Indianapolis, Indiana, United States
NOT_YET_RECRUITINGCone Health Moses Cone Hospital
Greensboro, North Carolina, United States
NOT_YET_RECRUITINGNC Heart and Vascular Research, LLC
Raleigh, North Carolina, United States
NOT_YET_RECRUITINGOhio State University
Columbus, Ohio, United States
NOT_YET_RECRUITINGSouth Oklahoma Heart Research, LLC
Oklahoma City, Oklahoma, United States
NOT_YET_RECRUITINGFakultní nemocnice Ostrava
Ostrava, Czech Republic, Czechia
NOT_YET_RECRUITINGSdružené zdravotnické zařízení Krnov
Krnov, Czechia
NOT_YET_RECRUITINGNemocnice Slaný
Slaný, Czechia
RECRUITINGAleksandre Aladashvili Clinic LLC
Tbilisi, Georgia
RECRUITINGLTD "Israeli-Georgian Medical Research Clinic Healthycore"
Tbilisi, Georgia
RECRUITING...and 33 more locations